Dr David Cook
David Cook is the Executive Vice President of R&D and Chief Scientific Officer of Seres Therapeutics, Inc. (“Seres”). He has over 20 years of experience as a scientist and entrepreneur and has held senior operating and management positions in the biotechnology industry throughout his career. Prior to joining Seres, he served as the Chief Operating Officer for the International AIDS Vaccine Initiative (IAVI), a global R&D organization. Prior to IAVI, Dr. Cook was the founding CEO at Anza Therapeutics, a biotechnology startup that focused on developing a microbial vaccine platform to induce cellular immune responses. Before launching Anza, Dr. Cook held positions of increasing responsibility at the biotechnology corporations Cerus and Eligix, overseeing R&D, program management, manufacturing, and clinical and regulatory affairs. He has led teams in the development and commercialization of several biotech products and has been directly responsible for obtaining marketing authorization from the European Union for four medical products. Dr. Cook is also a co-inventor on more than 25 patents. He earned his undergraduate degree from Harvard College and his Ph.D. in chemistry from the University of California, Berkeley.
Andrew Morgan
Dr Andrew Morgan is Chair of the UK’s KTN Microbiome Special Interest Group and has close to 40 years’ experience in health & nutrition research & innovation related to microbe-host interactions including human, animal and plant. He held the role of Chief Scientist to DuPont’s Nutrition & Health and legacy Danisco business (2008-2019) and was a DuPont Fellow. Having joined the company as a member of the pioneering FFI animal nutrition enzyme team, he then went on to play a key role in helping build DuPont’s microbiome platform. Andrew retired from DuPont at the end of 2019.
Juan Ramón Alaix
Juan Ramón Alaix is Chief Executive Officer of Zoetis. In this role, he leads the world’s leading animal health company with a singular focus on animal health medicines and vaccines, complemented by diagnostic products, genetic tests, biodevices and a range of services. In addition, he is a member of the Zoetis Board of Directors. Under his leadership, the company generated annual revenue of $4.9 billion in 2016 with approximately 9,000 employees worldwide.
Mr. Alaix has 35 years’ experience of increasing responsibility in finance, sales and management, including 20 years in the pharmaceutical industry. Prior to Zoetis, he served as President of Pfizer Animal Health since 2006, where he was responsible for the overall strategic direction and financial performance of the company. Mr. Alaix joined Pfizer from Pharmacia in 2003 as regional president. In the 1990s, he served in general management with Rhône-Poulenc Rorer in Spain and Belgium before becoming country president of Spain for Pharmacia in 1998.
Dr. Tony Zi Long Tan
Dr. Tan has over 30 years experience in the field of animal health across a range of animal species. He has had management roles in R&D, regulatory affairs, manufacturing, marketing, sales, and business development. Dr. Tan has extensive international business experience and has worked in the USA, Europe and Asia (particularly in China). Dr. Tan is the founder and Managing Partner of Z-Link Biotech Co. Ltd., a service and support company that helps animal health organizations to achieve their growth and stakeholder value in the emerging market.
Dr. Tan received his veterinary degree from Foshan Veterinary College in China, his Master’s Degree in Animal Science from Alcorn State University, and his Ph.D. in Microbiology from Kansas State University. During his earlier research career, Dr. Tan helped develop several vaccines for cattle, dogs, and poultry. He has published over 50 scientific publications and research reports.
Dr. Tan served Intervet-Schering Plough (now Merck/MSD Animal Health) for over 15 years in different positions, including R&D Group Leader, Project Manager Vaccine Manufacturing, Technical Marketing Manager Aquatic Animals, and Business Unit Director Companion Animals China.
From 2009 to March 2016, Dr. Tan was Group Director of Business Development and Global Alliances for the Asia-Pacific Region of Zoetis (formerly Pfizer Animal Health). He successfully completed several large M&A transactions (total transaction value in excess of US$100 million) and a number of technology licensing deals. These include the first antitrust divesture project in China, the company’s first joint venture project for vaccine manufacturing, and divesture of a pharmaceutical manufacturing plant in Taiwan.
Dr. Tan is an Advisor to the China Global Investment & Trading Alliance (CGITA), an organization that promotes international business between China and other countries.
谭博士在动物保健领域从业超过30年，涉及各种动物品种和岗位部门，包括研发、产品注册、生产、市场、销售以及业务拓展。谭博士拥有丰富的国际工作经验，曾在美国、欧洲和亚洲（特别是中国）国家工作。谭博士是易联生物科技有限公司的创始人。易联生物科技是一家咨询公司帮助动保公司在新兴市场服的发展。
谭博士毕业于佛山兽医专科学校、从阿尔肯州立大学取得了动物科学的硕士学位、从堪萨斯州立大学取得了微生物学的博士学位。在他的研究生涯中，为牛、狗以及家禽类开发了数种疫苗，并且发表了超过50篇科学论文和研究报告。
谭博士在英特威/默沙东动物保健公司工作了超过15年，期间担任了不同职位，包括研发部主管、疫苗制造项目经理、水生动物的技术市场经理以及中国伴侣动物的事业部总监。
从2009年到2016年，谭博士在硕腾（原名辉瑞）担任业务拓展部门和国际联盟亚太地区高级总监。他成功地完成了数项重大企业并购交易（总交易额超过一亿美元）和若干技术转让项目。其中包括中国第一个反垄断剥离项目，辉瑞在中国的第一个合资企业和出售台湾的一家医药制造工厂。
此外，谭博士还是中国际投资和贸易联盟(CGITA)的顾问。CGITA是一个致力于促进中国和其他国家之间国际商务的组织。
Ruiai Chen
Dr. Ruiai Chen received her Ph.D. in Microbiology from the China Agricultural University. Currently she is a professor and Ph.D. advisor at the College of Veterinary Medicines, South China Agricultural University.
Dr. Chen is President of Guangdong Wens Dahuanong Biotechnology Co., Ltd. (DHN), and Vice-Chairman of the China Veterinary Drug Association (CVDA). She is one of the most influential leaders in the Chinese animal health arena and, as a result, she is entitled to special allowances provided by the Chinese State Council, an honor for outstanding scientists in China. Dr. Chen is a well-known expert in the prevention and control of animal diseases, and vaccine research.
She possesses 41 patents and 22 new veterinary drug certificates. Dr. Chen has received 14 technical awards at the provincial and national levels, such as first prize for the Guangdong Provincial Science and Technology Award and the China Outstanding Patent. Her achievements include the development and industrialization of avian influenza vaccines, PRRS vaccines and coccidiosis vaccines. These vaccines are now making great contributions to disease control in China, Southeast Asia (e.g., Indonesia), and Middle East countries. Dr. Chen is also director of the Enterprise Key Laboratory of MOA for Animal Disease Prevention and Control, Biotechnology and Biological Product R&D. She has contributed greatly to commercialization of technology for animal vaccine and pharmaceutical products.
Norman Lee
Norman Lee, Ph.D., Professor and founder of Tianjin Ringpu Bio-Technology Co. Ltd., Director of the MOA’s Key Laboratory for Veterinary Drug Innovation, Chairman of the National Veterinary Drug Industry Strategic Alliance for Technology and Innovation, Vice-President of the Chinese Veterinary Association, President of the Tianjin Veterinary Medicine Association, post-graduate advisor at the Tianjin Agricultural University. Dr. Lee has led over 21 national, provincial, and municipal science and technology projects. He was recipient of the second prize of the National Science and Technology Progress Award and twice of the first prize of the Tianjin Science and Technology Progress Award.
In 1998, Dr. Lee established Ringpu(Tianjin)Bio-Pharmacy Co. Ltd. And Ringpu (Baoding) Biological Pharmaceutical Co., Ltd. He also acted as General Manager of both companies.
In 2004, he was in charge of the research project: “Genetically engineering recombinant chicken α- interferon”. The project received the first prize of the Tianjin City Technology Innovation Award.
In 2008, he led a management team to restructure the company and established Tianjin Ringpu Bio-Technology Co. Ltd. He was appointed Acting Chairman of the Board.
On 17th September 2010, Tianjin Ringpu Bio-Technology Co. Ltd. was officially listed on the Shenzhen Stock Exchange and Dr. Lee is Chairman of the Board,
In 2012, Dr. Lee was part of the research team: “Swine and poultry pathogenic bacteria resistance research and its application in development of a safe and effective new veterinary drug”. The project received the second prize of the National Science and Technology Progress Award.
Mr Sun Jinzhong
Mr.Sun Jinzhong was born in 1965, graduated from China agricultural university, major in veterinary , master degree, senior veterinary .He is vice chairman of PULIKE biological engineering co., LTD., Deputy Director of the National Research Center for Veterinary Medicine, Luoyang standing committee member , Vice President of China animal husbandry and veterinary institute – biological products branch, Deputy secretary-general of poultry epidemiology branch of China animal husbandry and veterinary institute council, China veterinary drug standard committee member, Vice chairman of Henan animal health products
association, Luoyang biological engineering expert technical committee member, Director and deputy secretary general the eighth session of board of Henan animal husbandry and veterinary institute, etc.
Mr Sun Jinzhong hosted and participated in various of science and technology projects, was awarded more than ten technology progress prizes as National, Henan province, Luoyang.Successively .He has won the qualifications and honorary titles as following:”Outstanding contribution high-level talent award of Luoyang high and new technology zone”, “Outstanding entrepreneurs of Luoyang high and new technology zone “, “the seventh batch of Luoyang excellent experts”, “Excellent leaguer of China Democratic League luoyang committee”, “Luoyang May 1 labor medal”, ” The third Luoyang excellent top 100 private science and technology industrialist “, “Advanced individual of promote agriculture by scientific technology in Henan province”, “Henan province government special allowance experts”.
孙进忠，1965年出生，毕业于中国农业大学兽医专业，硕士研究生学历，高级兽医师。现担任普莱柯生物工程股份有限公司副董事长职务，目前还担任国家兽用药品工程技术研究中心副主任、洛阳市政协常委、中国畜牧兽医学会生物制品学分会副理事长、中国畜牧兽医学会禽病学分会理事会理事兼任副秘书长、中国兽药典委员会委员、河南省动物保健品协会副会长、洛阳市生物工程专家技术委员会委员、河南省畜牧兽医学会第八届理事会理事、副秘书长等职务。
孙进忠先生主持、参与国家、省市各类科技项目多项，获国家、河南省、洛阳市科技进步奖10余项。先后荣获“洛阳市高新区突出贡献高层次人才奖”、“洛阳市高新区优秀企业家”、“第七批洛阳市优秀专家”、“民盟洛阳市委员会优秀盟员”、“洛阳市五一劳动奖章”、“洛阳市第三届优秀百佳民营科技实业家”、“河南省科技兴农先进个人”、“河南省政府特殊津贴专家”等资质、荣誉称号。
Yongsheng Wang
Dr. Zhao Yarong
Professor, Yarong ZHAO received Ph.D. in Veterinary Parasitology from China Agricultural University in 1993. With his cutting-edge researches in cryptosporidiosis, he received the First Grade Science & Technology Award from the Chinese Ministry of Agriculture in 1993.
From 1993 to 1998, he worked as National Technical Manager in Bayer Animal Health China. Later then in Fort Dodge Animal Health and Schering-Plough China as Regulatory and Technical Manager.
In 2003, he was appointed as General Manager of the Animal Medicine Research Center of the Dabeinong (DBN) Group, an innovative R&D center which focusing on animal infection disease diagnosis, animal biologic development and technology transfer. He has published over 50 scientific papers. Under his leadership, the Center has obtained Six National New Veterinary Drug Certificates and complete a number of technology transfer to other animal health companies with a total transaction value of approximately 350 million(RMB); Inactivated porcine circovirus type 2 (PCV2) vaccines, won the First Class State Science & Technology Progress Award in 2012.